Gilead Sciences Inc.: Access Program
Posted: 3 Apr 2010
Date Written: February 3, 2010
Abstract
Gilead Sciences, the U.S. leader in HIV/AIDS medicines, with global sales of $5.4 billion in 2009, had undertaken several innovative actions to make its anti-viral products available to over 100 low- and middle-income countries. Having reached nearly 680,000 patients by the middle of 2009, the company's senior managers contemplated how to reach 2 million patients by 2012.
Suggested Citation: Suggested Citation
Rangan, V. Kasturi and Lee, Katharine L., Gilead Sciences Inc.: Access Program (February 3, 2010). HBS Case No. 510-029, Harvard Business School Marketing Unit, Available at SSRN: https://ssrn.com/abstract=1581428
Katharine L. Lee
Harvard University - Business School (HBS) ( email )
Soldiers Field Road
Morgan 270C
Boston, MA 02163
United States
Feedback
Feedback to SSRN